CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for RegenoCELL Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

RegenoCELL Therapeutics Inc
2 Briar Ln
Phone: (508) 647-4065p:508 647-4065 NATICK, MA  01760-1040  United States
On 9/10/2015, the U.S. Securities and Exchange Commission revoked the registration of each class of registered securities of RegenoCELL Therapeutics Inc for failure to make required periodic filings with the Commission.
This company is no longer actively traded on any major stock exchange.
Business Summary
RegenoCELL Therapeutics, Inc. is engaged in providing adult stem cell therapy for autologous treatment of patients. The Company provides treatments for congestive heart failure and peripheral artery disease. The Company utilizes adult stem cells, which are derived from the patient's own blood, which eliminates the ethical and safety concerns associated with embryonic and umbilical cord blood stem cells. The Company's RCLLaes therapy utilizes a process to identify adult stem cells found in a patientaes blood. The Company's manufacturing operations are located in Israel. The Company's wholly owned subsidiary Regenocell Laboratories, Ltd., manufactures stem cell therapy products, which are used to treat congestive heart failure and peripheral artery disease. The Company, through its wholly owned subsidiary Regenocell, Ltd., is engaged in marketing stem cell therapy products either directly or through distributors.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/201112/31/2011YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research
2835 In vitro and in vivo diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, President, Chief Executive Officer, Treasurer, Secretary James F.Mongiardo 66 7/16/2008 7/16/2008
Secretary Joanna C.Coogan 38 1/26/2011 1/26/2011

Business Names
Business Name
International Business Corporation.
Regenocell Laboratories, Ltd.
RegenoCELL Therapeutics, Inc.
Regenocell, Ltd.

General Information
Number of Employees: 1 (As of 3/31/2012)
Outstanding Shares: 81,962,500 (As of 12/31/2011)
Shareholders: 30
Stock Exchange: OTC
Federal Tax Id: 223880440


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023